SEC Form SD filed by Bio-Rad Laboratories, Inc.

$BIO
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $BIO alert in real time by email
SD 1 d518963dsd.htm SD SD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form SD

 

 

SPECIALIZED DISCLOSURE REPORT

 

 

Bio-Rad Laboratories, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

DELAWARE   1-7928   94-1381833

(State or Other Jurisdiction of

Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

1000 Alfred Nobel Drive, Hercules, California   94547
(Address of Principal Executive Offices)   (Zip Code)

 

                                                     Timothy S. Ernst   (510) 741-6005                                                     

(Name and telephone number, including area code, of the person

to contact in connection with this report.)

 

 

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

☒  Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2020.

 

 

 


Section 1 - Conflict Minerals Disclosure

Item 1.01 Conflict Minerals Disclosure and Report

Bio-Rad Laboratories, Inc. (the “Company”) evaluated its current product lines and determined that tin, tungsten, tantalum and gold (“3TG”) are necessary to the functionality or production of certain products manufactured by the Company or contracted by the Company to be manufactured and are required to be reported in the calendar year covered by this specialized disclosure report. Accordingly, the Company conducted in good faith a reasonable country of origin inquiry regarding the 3TG in our products that was reasonably designed to determine whether any such 3TG originated in the Democratic Republic of the Congo or an adjoining country or were from recycled or scrap sources.

Conflict Minerals Disclosure

Based on our reasonable country of origin inquiry, we have filed a Conflict Minerals Report, which is attached hereto as Exhibit 1.01 and is publicly available at the Investor Relations section of our Web site, http://www.bio-rad.com/en-us/corporate/corporate-governance. The content of our Web site referred to in this Form SD is included for general information and is not incorporated by reference in this Form SD.

Item 1.02 - Exhibit

See Exhibit 1.01 attached hereto.

Section  2 - Exhibits

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.

 

       

    BIO-RAD LABORATORIES, INC.

    (Registrant)

 
  Date:  

May 17, 2021                         

 

    /s/ Timothy S. Ernst

 
       

    Timothy S. Ernst

 
       

    EVP, General Counsel and Secretary

 

 

Get the next $BIO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIO

DatePrice TargetRatingAnalyst
10/1/2024$350.00 → $400.00Neutral → Buy
Citigroup
8/28/2024$340.00Equal Weight
Wells Fargo
6/3/2024$315.00Hold
Jefferies
4/3/2024$400.00 → $365.00Buy → Neutral
Citigroup
12/7/2023$395.00Buy
UBS
6/16/2023$550.00Overweight
Wells Fargo
12/7/2022$565.00Outperform
RBC Capital Mkts
8/25/2022$715.00Outperform
Credit Suisse
More analyst ratings

$BIO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

    LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (NASDAQ:BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and diagnostics products, contributed to new research findings from Friends of Cancer Research's (Friends') ctMoniTR Project, recently published in Clinical Cancer Research (CCR). The findings demonstrate a strong association between changes in levels of circulating tumor DNA (ctDNA) and treatment outcomes, offering the potential for integration of ctDNA analysis in therapeutic development programs, and clinical cancer care. The ctMoniTR Project (ctDNA to Monitor Treatm

    $BDSX
    $BIO
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available

    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

    Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded clinical kitted product development with $50+ million in equity raisesAdvanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the

    $BIO
    $OCX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$BIO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BIO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BIO
SEC Filings

See more

$BIO
Leadership Updates

Live Leadership Updates

See more
  • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    $AAL
    $ADMA
    $ADNT
    $AMCX
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D

    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Officer responsible for all finance-related functions supporting the company's global operations since 2018. Prior to Benchmark, he held Chief Financial Officer and senior operational roles at several large, multinational companies including Suppo

    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$BIO
Financials

Live finance-specific insights

See more
  • Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available

    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: "Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business returned to a more normalized growth rate, and our ongoing transformation initiatives and diligent cost management helped improve our gross margins." Mr. Schwartz continued: "We begin 2025 in a strong position and remain committed to advancing

    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of 2024 on Thursday, February 13, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast wi

    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$BIO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more
  • SEC Form SC 13G/A filed

    SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • SEC Form SC 13G filed

    SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials